

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT3704237

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
NOVARTIS VACCINE AND DIAGNOSTICS INC.	12/08/2015
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	GlaxoSmithKline Biologicals SA
<b>Street Address:</b>	rue de l'Institut 89
<b>City:</b>	Rixensart
<b>State/Country:</b>	BELGIUM
<b>Postal Code:</b>	B-1330
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
Patent Number:	8178086
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(610)270-5090
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	610-270-6812
<b>Email:</b>	US_CIPKOP@GSK.com
<b>Correspondent Name:</b>	GLAXOSMITHKLINE
<b>Address Line 1:</b>	709 SWEDELAND ROAD
<b>Address Line 2:</b>	CIP UW2220
<b>Address Line 4:</b>	KING OF PRUSSIA, PENNSYLVANIA 19406
<b>ATTORNEY DOCKET NUMBER:</b>	VN52029
<b>NAME OF SUBMITTER:</b>	ARLENE E CANNON
<b>SIGNATURE:</b>	/Arlene E Cannon/
<b>DATE SIGNED:</b>	01/20/2016
<b>Total Attachments: 1</b>	
source=VN52029 US confirmatory assignment#page1.tif	

## CONFIRMATORY ASSIGNMENT

WE, **NOVARTIS VACCINES AND DIAGNOSTICS, INC.** a company incorporated under the State of Delaware, United States of America (registration number 2108457) and whose registered office is 2711 Centerville Road, Suite 400, Wilmington Delaware 19808 United States of America do hereby declare that we are the sole owner of the following patent(s)/patent application(s):

Canada Application Number 2636032 filed 4 January 2007 entitled Activation of HCV-Specific T Cells

United States Patent 8178086 granted 11 February 2010 entitled HCV-Specific T Cells

And in accordance with the Intellectual Property Assignment Agreement dated 2 March 2015 between **NOVARTIS VACCINES AND DIAGNOSTICS, INC.** and **GLAXOSMITHKLINE BIOLOGICALS SA**, for good and valuable consideration, the receipt of which is hereby acknowledged, we **NOVARTIS VACCINES AND DIAGNOSTICS, INC.** have assigned the entire right, title and interest and from which priority may be claimed from one or more applications, or any division, continuation and continuation-in-part of said application to in and to said patent application and all countries in which this/ these application(s) are filed to **GLAXOSMITHKLINE BIOLOGICALS SA** of Rue de l'Institut 89, 1330 Rixensart, Belgium


Dated this 8 day of December 2015.

Signed for and on behalf of  
**NOVARTIS VACCINES AND DIAGNOSTICS, INC.**



\_\_\_\_\_  
Helen Lee  
Authorized Attorney on behalf of  
**NOVARTIS VACCINES AND DIAGNOSTICS, INC.**

Signed for and on behalf of  
**GLAXOSMITHKLINE BIOLOGICALS SA**



\_\_\_\_\_  
Lorraine B. Ling  
Authorized Official on behalf of  
**GLAXOSMITHKLINE BIOLOGICALS SA**